This was the stock's second consecutive day of gains.

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical ...

BlackRock Mid Cap Growth Equity Fund reported 0.72% returns for 3Q2025. Review our latest analysis to learn how selective ...

Old Republic International announced an ORI special dividend of $2.50/share. Analysts like Raymond James and Piper Sandler ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

As the year comes to a close, it's time to look back at the numerous innovations across the diabetes technology industry in ...

Modine stock activity shows mixed signals. While one firm cut holdings, others increased stakes. Despite strong earnings, CEO ...

Fidelity Growth Strategies Fund outperformed its benchmark this quarter driven by strong stock selection in industrials.

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 24, 2025 ...